WO2010067986A3 - Composition for controlling gastrointestinal tract movement - Google Patents

Composition for controlling gastrointestinal tract movement Download PDF

Info

Publication number
WO2010067986A3
WO2010067986A3 PCT/KR2009/007215 KR2009007215W WO2010067986A3 WO 2010067986 A3 WO2010067986 A3 WO 2010067986A3 KR 2009007215 W KR2009007215 W KR 2009007215W WO 2010067986 A3 WO2010067986 A3 WO 2010067986A3
Authority
WO
WIPO (PCT)
Prior art keywords
composite composition
intestinal motility
motility disorder
controlling
movement
Prior art date
Application number
PCT/KR2009/007215
Other languages
French (fr)
Korean (ko)
Other versions
WO2010067986A2 (en
Inventor
박영준
조관형
최용규
Original Assignee
삼일제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삼일제약주식회사 filed Critical 삼일제약주식회사
Publication of WO2010067986A2 publication Critical patent/WO2010067986A2/en
Publication of WO2010067986A3 publication Critical patent/WO2010067986A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention provides a novel composite composition for controlling gastrointestinal tract movement comprising an enkephaline receptor agonist and a prokinetic agent. The composite composition provided according to the present invention is a general purpose composite composition for controlling movement of the upper and lower gastrointestinal tracts that enables improved movement controlling capabilities of the upper and lower gastrointestinal tracts in a complementary fashion, based on mutually different mechanisms of an enkephaline receptor agonist and a prokinetic agent. Thus, this is a novel composite composition that exhibits inclusive and effective therapeutic actions on various diseases including functional gastrointestinal disturbance, constipation, and irritable bowel syndrome as well as diabetic intestinal motility disorder, intestinal motility disorder caused by chemotherapy, ileus caused by intestinal motility disorder, and intestinal motility disorder in myotonic dystrophy patients.
PCT/KR2009/007215 2008-12-08 2009-12-04 Composition for controlling gastrointestinal tract movement WO2010067986A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0124068 2008-12-08
KR1020080124068A KR100991032B1 (en) 2008-12-08 2008-12-08 Novel Pharmaceutical Composition For Effective Control Of GI Motility

Publications (2)

Publication Number Publication Date
WO2010067986A2 WO2010067986A2 (en) 2010-06-17
WO2010067986A3 true WO2010067986A3 (en) 2010-09-10

Family

ID=42243174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007215 WO2010067986A2 (en) 2008-12-08 2009-12-04 Composition for controlling gastrointestinal tract movement

Country Status (2)

Country Link
KR (1) KR100991032B1 (en)
WO (1) WO2010067986A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101154043B1 (en) 2011-07-01 2012-06-07 주식회사 에코덤 Pharmaceutical composition and food composition for preventing or improving gastro-intestinal motility disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548501B2 (en) * 2000-05-31 2003-04-15 Pfizer Inc. Composition and methods for stimulating gastrointestinal motility
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548501B2 (en) * 2000-05-31 2003-04-15 Pfizer Inc. Composition and methods for stimulating gastrointestinal motility
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OK HWA JHEE ET AL.: "Pharmacokinetic and bioequivalence evaluation of two or mulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers sing the LC-MS/MS method", CLIN. CHIM. ACTA., vol. 375, no. 1-2, January 2007 (2007-01-01), pages 69 - 75 *

Also Published As

Publication number Publication date
KR20100065643A (en) 2010-06-17
WO2010067986A2 (en) 2010-06-17
KR100991032B1 (en) 2010-10-29

Similar Documents

Publication Publication Date Title
WO2010027567A3 (en) Tricyclic spirocycle derivatives and methods of use thereof
CL2007003261A1 (en) COMPOUNDS DERIVED FROM 1,4-BENZOTIEPINA-1,1-DIOXIDE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF LIPID METABOLISM DISORDERS, HYPERLIPIDEMIA, INSULIN RESISTANCE, DIABETES AND CNS DISORDERS, SUCH AS SCHIZOPHRENIA,
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2007067616A3 (en) Uses of myostatin antagonists
CL2008001125A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.
EA201891432A1 (en) SUBSTITUTED 4-PHENYLPYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS
MX2015001500A (en) Antidiabetic tricyclic compounds.
CL2008001126A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINONE CONDENSED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME AND OBESITY.
WO2007104789A3 (en) Amylin derivatives
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
CY1112398T1 (en) CYROLOXYL PYROLYLIDINE SUBSTITUTES AS 11-B-HYDROXYSTEROHYDROHYDROHOUSE INHIBITIONS 1
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
WO2007148208A3 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
EA201170198A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS
CL2007003629A1 (en) ARIL-SUBSTITUTED HETEROCICLIC COMPOUNDS, TYPE I CANNABINOID RECEIVER MODULATORS (CB1); PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS METABOLIC DISORDERS AND COGNITIVE DISORDERS.
CL2010001496A1 (en) Compounds derived from (pyridin- or pyrimidin-) piperidine, gpr119 agonists; pharmaceutical composition; and its use for the treatment of type I diabetes, type II diabetes and related diseases such as metabolic syndrome, dyslipidemia and insulin resistance.
WO2010127856A8 (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
SV2009003275A (en) DERIVATIVES OF AZACICLOALCANS AS INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA
EP2560660A4 (en) Chemosensory receptor ligand-based therapies
WO2008019147A3 (en) Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
EA201100910A1 (en) TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE BETA-DEFENSINS OF MAMMALS
WO2010045303A3 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832071

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09832071

Country of ref document: EP

Kind code of ref document: A2